CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CENTURY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/11/2022 | 01:22pm EDT

Item 7.01 Regulation FD Disclosure

On January 11, 2022, Century Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits


The following exhibit is being furnished herewith:



Exhibit
No.                                       Document

  99.1       Investor Presentation of Century Therapeutics, Inc., dated January
           11, 2022

104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document)

© Edgar Online, source Glimpses

All news about CENTURY THERAPEUTICS, INC.
05/17Piper Sandler Adjusts Century Therapeutics' Price Target to $22 From $38, Reiterates Ov..
MT
05/16Century Therapeutics Q1 Net Loss Narrows; Posts Revenue of $1.1 Million
MT
05/16CENTURY THERAPEUTICS, INC. Management's discussion and analysis of financial condition..
AQ
05/16Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business..
GL
05/12William Blair Initiates Coverage on Century Therapeutics With Market Perform Rating
MT
05/10CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
05/02Century Therapeutics to Present at the ASGCT 25th Annual Meeting
GL
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 272 M - -
Net income 2022 -135 M - -
Net cash 2022 127 M - -
P/E ratio 2022 -3,70x
Yield 2022 -
Capitalization 501 M 501 M -
EV / Sales 2022 1,38x
EV / Sales 2023 16,3x
Nbr of Employees 179
Free-Float 63,4%
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,51 $
Average target price 24,60 $
Spread / Average Target 189%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.-47.04%494
MODERNA, INC.-46.35%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.46%38 185
SEAGEN INC.-9.68%26 255
ICON PUBLIC LIMITED COMPANY-30.22%17 418